Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia. Aims: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice. Methods: This was an observational, multicenter, single-arm study. Pa...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-01-01
|
| Series: | Indian Heart Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0019483215000115 |